3 Top Stock Buybacks – Week of 1/14

Targeting stocks with recently announced buyback programs can be beneficial for investors. Buyback programs can be seen as a signal of confidence by the company’s management in the future prospects of the business. When a company announces a buyback program, it indicates that it believes its stock is undervalued and that it has excess cash available to repurchase shares, which can be interpreted as a positive sign for investors. Buybacks can also potentially increase the value of the remaining shares by reducing the total number of shares outstanding, which could lead to higher earnings per share and potentially higher stock prices.

Here are three stock buybacks for the week –

Amarin Corporation plc – SYM: AMRN
Recent Price: $1.18
Buyback Action: The Board of Directors approved a new $50 million share repurchase program, equal to around 12% of its market cap at announcement.
Description: Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Elon Musk’s THREE Startups Created an “Army of Millionaires”


Elon Musk’s last three startups were PayPal, SpaceX, and Tesla.

Online payments, electric cars, and rockets into space.

Just $300 into those startups could’ve turned into $647,000.

That’s why the BBC said that Elon helped create “an army of millionaires.”

Can Elon create another army of millionaires with his new AI startup?

Here’s a 2-minute video that shows Elon’s AI in action.
Click here to see the insane footage.


Taylor Morrison Home Corporation – SYM: TMHC
Recent Price: $51.34
Buyback Action: The Board of Directors announced that it had approved a new $500 million stock repurchase agreement. This represents around 8% of its market cap at announcement.
Description: Taylor Morrison Home Corporation, together with its subsidiaries, operates as a public homebuilder in the United States. The company designs, builds, and sells single and multi-family detached and attached homes; and develops lifestyle and master-planned communities. It also develops and constructs multi-use properties consisting of commercial space, retail, and multi-family properties under the Urban Form brand name; and offers title insurance and closing settlement services, as well as financial services. In addition, the company operates under the Taylor Morrison, Darling Homes Collection by Taylor Morrison, and Esplanade brand names in Arizona, California, Colorado, Florida, Georgia, Nevada, North and South Carolina, Oregon, Texas, and Washington. Taylor Morrison Home Corporation was founded in 1936 and is headquartered in Scottsdale, Arizona.

10 Best Stocks to Own in 2024

Enter your email address below and we’ll send you MarketBeat’s list of the 10 best stocks to own in 2024 and why they should be in your portfolio. You will also receive our free daily email newsletter with the latest buy and sell recommendations from Wall Street’s top analysts.

Send my free report!


Corcept Therapeutics Incorporated – SYM: CORT
Recent Price: $23.22
Buyback Action: The Board of Directors announced that it had approved a new $200 million stock repurchase agreement. This represents around 7% of its market cap at announcement.
Description: Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing’s syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

4 dividend stocks paying you 4 checks every month

What if I told you that there are 4 stocks that can pay you monthly dividends for life? That’s right – you can collect 4 checks every single month! One of these stocks currently pays a 17% yield and the other three have impressive dividend yields of 13%, 10% and 7%. And the best part? Their dividends are only getting bigger. No credit card is required to see these 4 stocks. Don’t wait any longer to start collecting your monthly dividend checks for life.

Get your FREE copy of this book here.

deal of the month

best growth stocks


Bundle package – lifetime subscriptions for all products


Recent posts


Connect with Us

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.